Honeywell has unveiled Aclar Edge, a pharmaceutical packaging solution for oral liquids for human health and sterile injectables for animal health applications. Designed with Honeywell’s novel and proprietary multi-layer extrusion blow molding technology, Aclar Edge bottles and vials are designed to preserve shelf-life and efficacy for a large variety of liquid dosage forms while improving user safety during the handling and administration.
According to Honeywell, Aclar Edge bottles and vials provide a moisture barrier performance that is comparable with glass and an enhanced oxygen barrier compared to other polymeric containers. In addition, Aclar Edge offers impact resistance and up to 75% weight reduction versus glass. Aclar Edge offers operational advantages by eliminating glass breakage, minimizing drug particulate contamination and reducing transportation cost. And unlike most plastic bottles used for liquids, Aclar Edge reduces the risk of leachables from the container closure systems.
“Glass bottles pose many challenges to the pharmaceutical industry as they are susceptible to cracking and breaking, inorganic leachables, and glass particulates. Aclar Edge is a novel technology that overcomes these issues and can improve drug product stability, purity and ultimately patient safety,” said Kori Anderson, general manager, healthcare packaging, at Honeywell.
Aclar Edge bottles and vials range in sizes from 100 ml to 500 ml and can be configured in threaded or crimped finish; commercial production will start in Q4 2020 for non-sterilized or gamma-sterilized formats. Pre-production samples of Aclar Edge are available now for customer evaluation.
